[Leucemogenesis of chronic myelogenous leukemia].
Chronic myelogenous leukemia is a model for the explaining between dysregulation of tyrosine-kinase and cellular transformation. BCR-ABL protein providing from the abnormal gene is the biological marker of the leukemic cells. It is the molecular counterpart of the chromosomal abnormality that is also called Philadelphia chromosome. Since BCR-ABL drives the leukemic proliferation, it became recently a specific target to develop the tyrosine-kinase inhibitors. These new specific drugs and their effects on the chronic myelogenous leukemia must be taken into account to explain the physiopathology of the disease.
Mahon
François-Xavier
FX
Laboratoire d'hématologie, CHU de Bordeaux, Inserm E0217, Université Victor Segalen-Bordeaux 2, 33076 Bordeaux Cedex. francois-xavier.mahon@umr5540.u-bordeaux2.fr
D000970:Antineoplastic Agents / Q000494:pharmacology; D002471:Cell Transformation, Neoplastic; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D016313:Genes, abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000503:physiopathology*; D011487:Protein Conformation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl